Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Yuhan Corporation
  6. Summary
    A000100   KR7000100008

YUHAN CORPORATION

(A000100)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
63800 63800 64200 64800 65200 Last
201679 172666 288309 387055 244657 Volume
+0.31% 0.00% +0.63% +0.93% +0.62% Change
Financials
Sales 2021 1 734 B 1,55 B 1,55 B
Net income 2021 105 B 0,09 B 0,09 B
Net cash position 2021 357 B 0,32 B 0,32 B
P/E ratio 2021 41,9x
Yield 2021 0,60%
Sales 2022 1 824 B 1,63 B 1,63 B
Net income 2022 115 B 0,10 B 0,10 B
Net cash position 2022 380 B 0,34 B 0,34 B
P/E ratio 2022 39,8x
Yield 2022 0,60%
Capitalization 4 261 B 3 813 M 3 818 M
EV / Sales 2021 2,25x
EV / Sales 2022 2,13x
Nbr of Employees 1 546
Free-Float 67,5%
More Financials
Company
Yuhan Corporation is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. Along with its subsidiaries, the Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and... 
Sector
Pharmaceuticals
Calendar
07/23Earnings Release
More about the company
Ratings of Yuhan Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about YUHAN CORPORATION
04/21MARKET CHATTER : Yuhan-Kimberly-Clark Joint Venture Joins Partnership to Create ..
MT
03/16MARKET CHATTER : Yuhan, Samsung Bioepis Enter Partnership to Market Humira's Bio..
MT
01/20MARKET CHATTER : South Korea's Drug Safety Agency Approves Yuhan's Non-Small Cel..
MT
01/19MARKET CHATTER : South Korea's Drug Safety Agency Approves Yuhan's Lung Cancer T..
MT
2020MARKET CHATTER : Janssen Biotech to Pay Yuhan $65 Million for Third-Gen Tyrosine..
MT
2020MARKET CHATTER : Top South Korean Pharma Companies' Third Quarter Results Surpas..
MT
More news
News in other languages on YUHAN CORPORATION
2019YUHANá : Boehringer Ingelheim kooperiert mit südkoreanischer Yuhan
More news
Chart YUHAN CORPORATION
Duration : Period :
Yuhan Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends YUHAN CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 84 721,77 KRW
Last Close Price 65 200,00 KRW
Spread / Highest target 53,4%
Spread / Average Target 29,9%
Spread / Lowest Target 6,60%
EPS Revisions
Managers and Directors
NameTitle
Jeong-Hui Lee President, Chief Executive Officer & Director
Sang-Chul Kim Director, Head-Research & Development
Han Kon Kim Head-Global Operations
Jong-Soo Lee Head-Compliance Support
In-Young Go Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
YUHAN CORPORATION-13.18%3 813
MERCK KGAA10.55%81 596
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD51.17%38 130
KYOWA KIRIN CO., LTD.31.66%18 130
SK BIOPHARMACEUTICALS CO., LTD.-28.11%8 516
BETTA PHARMACEUTICALS CO., LTD.-0.39%6 906